The Therapeutic Goods Administration’s (TGA) Advisory Committee on Medicines Scheduling has made an interim recommendation to reschedule codeine-containing products from S3 (Pharmacist Only Medicine) to S4 (Prescription Only Medicine) from June 2016. The decision is predicated on risk dependence and the adverse effects of codeine-based products compared to newly released forms of ibuprofen and paracetamol…

Read More